Stockhead on MSN3h
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...
GlobalData on MSN5d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
GlobalData on MSN2d
MacroGenics axes ADC drug following Phase II failure in prostate cancer
MacroGenics stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.
Applied Clinical Trials Online10d
Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Merck’s lupus drug fails in SLE cohort of Phase II trial
Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 earnings call, ...
Clinical Trials Arena on MSN17d
Persica’s antibiotic-based drug alleviates lower back pain in Phase Ib trial
Evidence has shown that 25% of patients with chronic lower back pain could be suffering from an infection in the disc space.
Yahoo Finance12d
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
On Monday, Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 ... REDEFINE 2 trial was based on a flexible protocol, allowing patients to modify their dosing throughout ...
Pharmabiz5d
EnteroBiotix reports positive results from TrIuMPH phase 2a trial of EBX-102-02 in adults with irritable bowel syndrome with constipation
Glasgow, Scotland Wednesday, March 19, 2025, 09:00 Hrs [IST] ...
Clinical Trials Arena on MSN3d
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...
Patrika News2d
Mounjaro, Diabetes and Weight-Loss Drug, Launched in India
American pharmaceutical company Eli Lilly has launched its drug, Mounjaro, in India. Mounjaro is administered as a ...
PharmiWeb2d
New AI technology could bring cancer drugs to patients in half the current time
Scientists have developed a revolutionary AI ‘fingerprint’ technology that can accurately show how cancer cells respond to ...